medigraphic.com
Órgano Oficial de el Colegio Mexicano de Urología

2006, Number 3

<< Back Next >>

Bol Col Mex Urol 2006; 21 (3)

Eficacia y tolerabilidad del clodronato vía oral para alivio del dolor en pacientes con cáncer de próstata metastásico

Bravo GVM, Fernández GAH, Carvajal GR

Language: Spanish
References: 50
Page: 79-84
PDF size: 35.55 Kb.


ABSTRACT

Introduction: The patients with bone metastasis by prostate cancer attend frequently with bone pain. The biphosphonates preserve the bone structure and the mineralization which can repel positively in the handling of the pain. Material and methods: Controlled clinical trial in patients with secondary bone pain to metastasis by prostate carcinoma. With an average age of 74.2 years. They administered 1,600 mg of oral clodronate daily by 13 weeks evaluating with visual analogue scale (VAS), Karnofsky Index and daily requirement of analgesic in analgesic/unit (U/A), initial, monthly and final; in addition to tolerability to the medicine. Results: The basal average of 6, 8 VAS was of ± 1.68 and 4.7 end of ± 1.15, with one differentiates significant from -2.1 ± 1.37 (p = 0.00046). The basal average of Karnofsky was of 65 ± 14.33 and to the three 73 months of ± 10.59. The difference in average was 8 6.324 (p = 0.0015). The basal determination of U/A per day average was of 3.826 1.49 U/A and in 2.364 final state ± 1.057 U/A with -1.462 a significant difference of ± 0.684 (p = 0.00004). Conclusions: The improvement in VAS and reduction of U/A observed in this study proposes that the clodronate use can be of clinical relevance in the handling of the patient with secondary bone pain to metastasis by prostate cancer.


REFERENCES

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.

  2. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-94.

  3. Pentyala SN, Lee J, Hsieh K, et al: Prostate cancer: A comprehensive review. Med Oncol 2000; 17: 85-105.

  4. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94.

  5. Mercadante S, Casuccio A, Pumo S, et al. Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home. J Pain Symptom Manage 2000: 20: 27-34.

  6. Tennvall J, Darte L, Lundgren R, et al. Palliation of multiple bone metastases from prostatic carcinoma with strontium- 89. Acta Oncol 1988; 27: 365-9.

  7. Correns HJ, Mebel M, Buchali K, et al. 89-Strontium therapy of bone metastases of carcinoma of the prostatic gland. Eur J Nucl Med 1979; 4: 33-5.

  8. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-93.

  9. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.

  10. 10.Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998; 16: 3890-9.

  11. 11.Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget’s disease of bone from a Western Osteoporosis Alliance symposium: Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9–10, 2000. Clin Ther 2001; 23: 620-6.

  12. 12.Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-91.

  13. 13.Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-44.

  14. 14.Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082-90.

  15. 15.Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983; 74: 421-32.

  16. 16.Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-67.

  17. 17.Nussbaum SR, Younger J, VandePol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297-304.

  18. 18.Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebocontrolled trial—Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-54.

  19. 19.Marquardt H, Lioubin MN, Ikeda T. Complete amino acid sequence of human transforming growth factor type beta 2. J Biol Chem 1987; 262: 12127-31.

  20. 20.Mayahara H, Ito T, Nagai H, et al. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 1993; 9: 73-80.

  21. 21.Dunstan CR, Boyce R, Boyce BF, et al. Systemic administration of acidic fibroblast growth factor (FGF- 1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 1999; 14: 953-9. 22.Izbicka E, Dunstan C, Esparza J, et al. Human amniotic tumor that induces new bone formation in vivo produces growthregulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Res 1996; 56: 633-6.

  22. 23.Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166: 2023-31.

  23. 24.Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74-80.

  24. 25.Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69: 64-70. 26.Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 858-64. 27.Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13: 41-9.

  25. 28.Taube T, Kylmala T, Lamberg-Allardt C, et al. The effect of clodronate on bone in metastatic prostate cancer: Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer 1994; 30: 751-8.

  26. 29.Clarke NW, Holbrook IB, McClure J, et al. Osteoclast inhibition by pamidronate in metastatic prostate cancer: A preliminary study. Br J Cancer 1991; 63: 420-3.

  27. 30.Adami S, Salvagno G, Guarrera G, et al. Dichloromethylenediphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: 1152-4.

  28. 31.Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80: 1674-9.

  29. 32.Carey PO, Lippert MC. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 1998; 32: 403-7.

  30. 33.Cresswell SM, English PJ, Hall RR, et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995; 76: 360-5.

  31. 34.Kylmala T, Tammela TL, Lindholm TS, et al. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994; 83: 316-9.

  32. 35.Pelger RC, Hamdy NA, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22: 403-8.

  33. 36.Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain: A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992; 24: 159-66.

  34. 37.Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141: 85-7.

  35. 38.Strang P, Nilsson S, Brandstedt S, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997; 17: 4717-21.

  36. 39.Kylmala T, Taube T, Tammela TL, et al. Concomitant i.v. and oral clodronate in the relief of bone pain: A double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997; 76: 939-42.

  37. 40.Lipton A, Small E, Saad F, et al. The new bisphosphonate ZOMETATM (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: A comparison to pamidronate. Cancer Invest 2001; 20(Suppl.): 45-7.

  38. 41.Lipton A, Glover D, Harvey H, et al. Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994; 5: S31-S35.

  39. 42.Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38.

  40. 43.McCormack A, Hunter-Smith D, Piotrowski ZH, et al. Analgesic use in home hospice cancer patients. J Fam Pract 1992; 34: 160-4.

  41. 44.Foley KM, Inturrisi CE. Analgesic drug therapy in cancer pain: Principles and practice. Med Clin North Am 1987; 71: 207- 32.

  42. 45.Lyles KW, Lammers JE, Shipp KM, et al. Functional and mobility impairments associated with Paget’s disease of bone. J Am Geriatr Soc 1995; 43: 502-6.

  43. 46.Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-6.

  44. 47.Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999; 25: 97- 106.

  45. 48.Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001; 93: 534-8.

  46. 49.Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378-91.

  47. 50.Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.

  48. 51.Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51.

  49. 52.Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. J Natl Cancer Inst 2005; 97(1): 59-69.

  50. 53.Coleman RE. The Oncologist, Bisphosphonates. Clin Exp Oncol 2004; 9(Suppl. 4): 14-27.




2020     |     www.medigraphic.com